Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.52 |
| ▸ | NOS2 | P35228 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278135 | 0.90 | SLC7A5 (0.65) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL19668486 | 0.88 | NOS2 (0.50) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL11347253 | 0.85 | PPARG (0.46) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL9772691 | 0.85 | PPARG (0.46) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL8971176 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL8971145 | 0.82 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL8761190 | 0.81 | PPARG (0.48) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL2723434 | 0.81 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| SCHEMBL7052799 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 | |
| Oxalic Acid SCHEMBL8718092 | 0.80 | PPARG (0.44) | SLC6A2SLC6A4SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| EP-0969874-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE DERIVATIVES AND CYCLODEXTRIN | Therabel Industries S.A. (FR) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042382-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPANAMINE DERIVATIVES AND CYCLODEXTRIN | THERABEL INDUSTRIES S.A. (FR) | 1998-10-01 | — | — | WO | claimed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-0004447-B1 | PREPARATION OF TRIFLUOROMETHYLPHENOLS AND NOVEL TRIFLUOROMETHYLPHENYL BENZYL ETHER INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0004447-A2 | Preparation of trifluoromethylphenols and novel trifluoromethylphenyl benzyl ether intermediates | ELI LILLY AND COMPANY (US) | 1979-10-03 | — | — | EP | disclosed |
| US-4168388-A | Trifluoromethylphenyl benzyl ethers | ELI LILLY AND COMPANY (US) | 1979-09-18 | — | — | US | disclosed |